Page last updated: 2024-08-24

telmisartan and Atheroma

telmisartan has been researched along with Atheroma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, J; Li, YP; Shen, ZJ; Xia, P; Xu, CS; Xu, JJ1
Ise, T; Iwase, T; Kusunose, K; Niki, T; Oeduka, H; Sata, M; Soeki, T; Taketani, Y; Wakatsuki, T; Yamada, H; Yamaguchi, K1
Akaike, M; Bando, S; Hirata, Y; Iwase, T; Koshiba, K; Kusunose, K; Niki, T; Sata, M; Soeki, T; Taketani, Y; Tomita, N; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K1

Trials

1 trial(s) available for telmisartan and Atheroma

ArticleYear
Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:1

    Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Coronary Artery Disease; Cytokines; Female; Follow-Up Studies; Humans; Hypertension; Inflammation Mediators; Male; Plaque, Atherosclerotic; Telmisartan; Ultrasonography, Interventional

2014

Other Studies

2 other study(ies) available for telmisartan and Atheroma

ArticleYear
Telmisartan inhibits Ang II-induced MMP-9 expression in macrophages in stabilizing atheromatous plaque.
    European review for medical and pharmacological sciences, 2018, Volume: 22, Issue:22

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cell Line; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Humans; Macrophages; Matrix Metalloproteinase 9; Plaque, Atherosclerotic; Telmisartan

2018
Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability.
    Journal of cardiology, 2011, Volume: 58, Issue:2

    Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Sinus; Disease Progression; Drug Monitoring; Female; Humans; Inflammation Mediators; Male; Middle Aged; Plaque, Atherosclerotic; Serum Amyloid P-Component; Severity of Illness Index; Telmisartan; Tomography, Spiral Computed

2011